Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

The present study investigated the relationship between accumbal ghrelin and glucagon-
like peptide 1 (GLP-1) signaling in alcohol reward in female rats. Animals with guide …

An effort has been mounted to understand the mechanisms of alcohol dependence in a way
that may allow for greater efficacy in treatment. It has long been suggested that drugs of …

Glutamatergic neurotransmission has been suggested to modulate cue-induced drug-
seeking behavior. Here we examined the effects of metabotropic glutamate receptor …

Alcohol use disorder (AUD) is associated with the dysregulation of brain stress and reward
systems, including glucocorticoid receptors (GRs). The mixed glucocorticoid/progesterone …

Obesity is a major health problem worldwide resulting in numerous health conditions such
as heart disease, stroke, type 2 diabetes (T2D), and certain types of cancer which are …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Concerns over reports of suicidal ideation associated with semaglutide treatment, a
glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) …

The gastrointestinal tract secretes gut hormones in response to food consumption, and some
of these stimulate insulin secretion. Glucagon-like peptide-1 (GLP-1) is an incretin peptide …

Background/objectives The weight loss following Semaglutide treatment, a GLP-1 receptor
agonist, might be responsible for some effects observed on the nonalcoholic fatty liver …